CR10573A - Derivados del pirazol como inhibidores del citocromo p450 - Google Patents

Derivados del pirazol como inhibidores del citocromo p450

Info

Publication number
CR10573A
CR10573A CR10573A CR10573A CR10573A CR 10573 A CR10573 A CR 10573A CR 10573 A CR10573 A CR 10573A CR 10573 A CR10573 A CR 10573A CR 10573 A CR10573 A CR 10573A
Authority
CR
Costa Rica
Prior art keywords
citocromo
pirazol
inhibitors
derivatives
methods
Prior art date
Application number
CR10573A
Other languages
English (en)
Inventor
Paul Planken Simon
Channing Sutton Scott
Chen Rongliang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR10573A publication Critical patent/CR10573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona compuestos de formula (I), o sales o solvatos de los mismos farmaceuticamente aceptables, procedimientos para prepararlos, procedimientos para usarlos y formulaciones farmaceuticas que los comprenden.
CR10573A 2006-07-05 2009-01-20 Derivados del pirazol como inhibidores del citocromo p450 CR10573A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
CR10573A true CR10573A (es) 2009-02-12

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10573A CR10573A (es) 2006-07-05 2009-01-20 Derivados del pirazol como inhibidores del citocromo p450

Country Status (24)

Country Link
US (1) US7919488B2 (es)
EP (1) EP2046774A1 (es)
KR (1) KR20090034958A (es)
CN (1) CN101511812A (es)
AP (1) AP2009004763A0 (es)
AR (1) AR062154A1 (es)
AU (1) AU2007270814B2 (es)
CA (1) CA2660031A1 (es)
CO (1) CO6150178A2 (es)
CR (1) CR10573A (es)
EA (1) EA200900135A1 (es)
GT (1) GT200700053A (es)
IL (1) IL196490A0 (es)
MA (1) MA30629B1 (es)
MX (1) MX2009000482A (es)
NO (1) NO20090346L (es)
NZ (1) NZ574207A (es)
PE (1) PE20080998A1 (es)
RS (1) RS20090036A (es)
TN (1) TN2009000033A1 (es)
TW (1) TWI334867B (es)
UY (1) UY30460A1 (es)
WO (1) WO2008004096A1 (es)
ZA (1) ZA200900478B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005252A (es) * 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
JP2010521456A (ja) * 2007-03-13 2010-06-24 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
JP5878546B2 (ja) 2010-11-09 2016-03-08 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2014000178A1 (en) * 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
SI1373263T1 (en) * 2001-04-05 2005-04-30 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
GEP20115230B (en) * 2005-09-23 2011-06-10 Pfizer Prod Inc Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4

Also Published As

Publication number Publication date
TWI334867B (en) 2010-12-21
MA30629B1 (fr) 2009-08-03
NZ574207A (en) 2010-10-29
IL196490A0 (en) 2011-07-31
KR20090034958A (ko) 2009-04-08
ZA200900478B (en) 2010-04-28
GT200700053A (es) 2009-08-03
US20080021011A1 (en) 2008-01-24
PE20080998A1 (es) 2008-08-15
UY30460A1 (es) 2008-02-29
WO2008004096A1 (en) 2008-01-10
TN2009000033A1 (fr) 2010-08-19
US7919488B2 (en) 2011-04-05
RS20090036A (sr) 2010-06-30
CA2660031A1 (en) 2008-01-10
TW200811159A (en) 2008-03-01
AU2007270814B2 (en) 2011-07-14
NO20090346L (no) 2009-02-19
MX2009000482A (es) 2009-01-27
EA200900135A1 (ru) 2009-06-30
AR062154A1 (es) 2008-10-22
AP2009004763A0 (en) 2009-02-28
CN101511812A (zh) 2009-08-19
EP2046774A1 (en) 2009-04-15
CO6150178A2 (es) 2010-04-20
AU2007270814A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
UY30460A1 (es) Compuestos terapéuticos
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP088296A (es) Compuestos terapéuticos
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
ECSP099721A (es) Inhibidores de cinasa p70 s6
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201100130A (es) Derivados de pirimidin indol para el tratamiento de cáncer.
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
UY32203A (es) Amino pirimidinas y su uso en terapia
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY33075A (es) Derivados de ciclohexano y usos de los mismos
DOP2009000215A (es) Administracion semanal de inhibidores de peptidasa de pipeptidilo
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
AR078613A1 (es) Derivados de sulfoxidos benzooxazolicos y benzotriazolicos inhibidores de autotaxinas, medicamentos que los contienen y uso de los mismos para el tratamiento de tumores.
DOP2009000242A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer